Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Effectiveness of a Single Fixed Dose 3 mg Rasburicase for Prevention and Management of Hyperuricemia of Tumor Lysis Syndrome in adult Cancer Patients

Sabirin Bakhsh
,
Mansoor Ahmed Khan
* ORCID logo ,
Majed Alshamrani
,
Roula Mufti
,
Anjum Naeem Ansari
,
Mansour Almubarak
,
Ahmad Alsaeed
,
Mousa Alahmari
,
Muhammad Aseeri
Version 1 : Received: 14 May 2024 / Approved: 14 May 2024 / Online: 14 May 2024 (12:46:34 CEST)

How to cite: Bakhsh, S.; Khan, M. A.; Alshamrani, M.; Mufti, R.; Ansari, A. N.; Almubarak, M.; Alsaeed, A.; Alahmari, M.; Aseeri, M. Effectiveness of a Single Fixed Dose 3 mg Rasburicase for Prevention and Management of Hyperuricemia of Tumor Lysis Syndrome in adult Cancer Patients. Preprints 2024, 2024050962. https://doi.org/10.20944/preprints202405.0962.v1 Bakhsh, S.; Khan, M. A.; Alshamrani, M.; Mufti, R.; Ansari, A. N.; Almubarak, M.; Alsaeed, A.; Alahmari, M.; Aseeri, M. Effectiveness of a Single Fixed Dose 3 mg Rasburicase for Prevention and Management of Hyperuricemia of Tumor Lysis Syndrome in adult Cancer Patients. Preprints 2024, 2024050962. https://doi.org/10.20944/preprints202405.0962.v1

Abstract

Abstract: Effectiveness of a Single Fixed Dose 3 mg Rasburicase for Prevention and Management of Hyperuricemia of Tumor Lysis Syndrome in adult Cancer Patients Background: Tumor lysis syndrome (TLS) is a potentially life-threatening complication associated with certain types of cancer. Rasburicase is an essential medicine required to prevent and treat the hyperuricemia associated with TLS. Due to a shortage of rasburicase during the COVID-19 pandemic, a fixed dose strategy of 3 mg rasburicase had been used in many adult cancer patients in our center. Objective: The objective of this study was to assess the effectiveness of a 3 mg fixed dose of rasburicase in preventing and managing hyperuricemia associated with TLS in adult cancer patients. Methods: We conducted a retrospective, observational cohort study between March 2020 and November 2022. The study included adult patients who received a fixed dose of 3 mg rasburicase. The primary outcome measure was the reduction in serum UA levels of

Keywords

Rasburicase; Tumor Lysis syndrome; Cost-effectiveness; 3 mg single fixed dose

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.